Brief: Noxopharm Says Orphan Drug Designation Granted To Noxopharm By U.S. FDA
22/03/2022 01:17
March 22 (Reuters) - Noxopharm Ltd NOX.AX :
* ORPHAN DRUG DESIGNATION GRANTED TO NOXOPHARM BY US FDA
* UNITED STATES FDA GRANTS ORPHAN DRUG DESIGNATION TO
VEYONDA FOR
USE IN TREATMENT OF SOFT TISSUE SARCOMA
Source text for Eikon: ID:nASX9mgx8T
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer